NO300617B1 - Fremgangsmåte for fremstilling av et overflateterapeutisk system - Google Patents
Fremgangsmåte for fremstilling av et overflateterapeutisk system Download PDFInfo
- Publication number
- NO300617B1 NO300617B1 NO900270A NO900270A NO300617B1 NO 300617 B1 NO300617 B1 NO 300617B1 NO 900270 A NO900270 A NO 900270A NO 900270 A NO900270 A NO 900270A NO 300617 B1 NO300617 B1 NO 300617B1
- Authority
- NO
- Norway
- Prior art keywords
- particularly preferred
- matrix
- active substance
- adhesive
- protective layer
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 230000001225 therapeutic effect Effects 0.000 title claims description 6
- 239000000853 adhesive Substances 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920000058 polyacrylate Polymers 0.000 claims abstract description 16
- 239000011159 matrix material Substances 0.000 claims abstract description 15
- 230000001070 adhesive effect Effects 0.000 claims abstract description 14
- 239000010410 layer Substances 0.000 claims abstract description 10
- 239000011241 protective layer Substances 0.000 claims abstract description 8
- 230000035515 penetration Effects 0.000 claims abstract description 4
- 229940034982 antineoplastic agent Drugs 0.000 claims abstract 2
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 2
- 239000013543 active substance Substances 0.000 claims description 23
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 13
- 229960002949 fluorouracil Drugs 0.000 claims description 12
- 230000002745 absorbent Effects 0.000 claims description 8
- 239000002250 absorbent Substances 0.000 claims description 8
- 239000011888 foil Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229920001577 copolymer Polymers 0.000 claims description 5
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 5
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 5
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 4
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- 235000013772 propylene glycol Nutrition 0.000 claims description 4
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000008240 homogeneous mixture Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 1
- 239000006096 absorbing agent Substances 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000003974 emollient agent Substances 0.000 abstract 1
- 238000004381 surface treatment Methods 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- -1 polyethylene Polymers 0.000 description 5
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000001085 cytostatic effect Effects 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010048629 Wound secretion Diseases 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229920000298 Cellophane Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical class COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000023445 activated T cell autonomous cell death Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000760 phototoxic Toxicity 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011521 systemic chemotherapy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- General Preparation And Processing Of Foods (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3901551A DE3901551A1 (de) | 1989-01-20 | 1989-01-20 | Superfizielles therapeutisches system mit einem gehalt an einem antineoplastischen wirkstoff, insbesondere 5-fluoruracil |
Publications (3)
Publication Number | Publication Date |
---|---|
NO900270D0 NO900270D0 (no) | 1990-01-19 |
NO900270L NO900270L (no) | 1990-07-23 |
NO300617B1 true NO300617B1 (no) | 1997-06-30 |
Family
ID=6372429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO900270A NO300617B1 (no) | 1989-01-20 | 1990-01-19 | Fremgangsmåte for fremstilling av et overflateterapeutisk system |
Country Status (22)
Country | Link |
---|---|
US (1) | US5077055A (sv) |
EP (1) | EP0379933B1 (sv) |
JP (1) | JPH0784378B2 (sv) |
KR (1) | KR960008226B1 (sv) |
AT (1) | ATE112174T1 (sv) |
AU (1) | AU631167B2 (sv) |
CA (1) | CA2007353C (sv) |
CZ (1) | CZ278718B6 (sv) |
DD (1) | DD291478A5 (sv) |
DE (2) | DE3901551A1 (sv) |
DK (1) | DK0379933T3 (sv) |
ES (1) | ES2063172T3 (sv) |
FI (1) | FI104150B (sv) |
HU (1) | HU205013B (sv) |
IE (1) | IE66737B1 (sv) |
IL (1) | IL92924A (sv) |
NO (1) | NO300617B1 (sv) |
NZ (1) | NZ232158A (sv) |
PL (1) | PL163294B1 (sv) |
PT (1) | PT92903B (sv) |
SK (1) | SK13290A3 (sv) |
YU (1) | YU47339B (sv) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4020144A1 (de) * | 1990-06-25 | 1992-01-09 | Lohmann Therapie Syst Lts | Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen |
TW283163B (sv) * | 1993-08-19 | 1996-08-11 | Nissan Chemical Ind Ltd | |
JPH07206710A (ja) * | 1994-01-21 | 1995-08-08 | Nitto Denko Corp | 経皮投薬用テープ製剤 |
DE4416927C1 (de) * | 1994-05-13 | 1995-08-31 | Lohmann Therapie Syst Lts | Vorrichtung zur Abgabe von Wirkstoffen aus Haftschmelzklebern, Verfahren zu ihrer Herstellung und ihre Verwendung |
FR2738744B1 (fr) * | 1995-09-20 | 1997-10-24 | Oreal | Patch cosmetique ou dermo-pharmaceutique contenant dans une matrice polymerique au moins un compose actif en particulier instable en milieu oxydant et au moins un agent hydro-absorbant |
US6063398A (en) * | 1995-09-20 | 2000-05-16 | L'oreal | Cosmetic or dermopharmaceutical patch containing, in an anhydrous polymeric matrix, at least one active compound which is, in particular, unstable in oxidizing mediums, and at least one water-absorbing agent |
EP0793972B1 (en) * | 1996-03-09 | 2003-05-28 | Nitto Denko Corporation | Adhesive percutaneous preparation |
FR2787459B1 (fr) * | 1998-12-18 | 2001-02-16 | Oreal | Solution d'un polymere du type polyacrylique et/ou polyvinylique associe a une charge et a un agent keratolytique et dispositif cosmetique de nettoyage et de soin |
DE19925519A1 (de) * | 1999-06-04 | 2000-12-07 | Lohmann Therapie Syst Lts | Wundauflage zur gesteuerten Abgabe von Wirkstoff an Wunden und Verfahren zu ihrer Herstellung |
DE10025328A1 (de) * | 2000-05-23 | 2001-12-06 | Lohmann Therapie Syst Lts | Acetylsalicylsäure enthaltendes superfizielles therapeutisches System zur Behandlung von Hautschmerzen |
FR2826261B1 (fr) * | 2001-06-26 | 2005-03-25 | Lmd | Composition a usage topique comprenant un produit cytotoxique et son utilisation dans le traitement de l'alopeche |
ITMI20041628A1 (it) * | 2004-08-06 | 2004-11-06 | Bouty S P A | Sistema terapeutico a rilascio controllato per uso topico transdermico |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3734097A (en) * | 1969-04-01 | 1973-05-22 | Alza Corp | Therapeutic adhesive tape |
US3769071A (en) * | 1971-06-04 | 1973-10-30 | Minnesota Mining & Mfg | Pressure sensitive adhesive tape comprising 5-fluorouracil |
IN155486B (sv) * | 1981-03-16 | 1985-02-09 | Johnson & Johnson Prod Inc | |
JPS60123417A (ja) * | 1983-12-07 | 1985-07-02 | Nitto Electric Ind Co Ltd | 薬物投与部材 |
US4697202A (en) * | 1984-02-02 | 1987-09-29 | Sri International | Integrated circuit having dislocation free substrate |
JPH0667835B2 (ja) * | 1984-03-01 | 1994-08-31 | サンド・アクチエンゲゼルシヤフト | 医薬組成物 |
DE3513938A1 (de) * | 1985-04-18 | 1986-10-23 | Merck Patent Gmbh, 6100 Darmstadt | Cytostatikahaltiges pharmakadepot |
EP0224981A3 (en) * | 1985-11-04 | 1988-08-10 | Paco Research Corporation | Nitroglycerin transdermal delivery system |
WO1987007154A1 (en) * | 1986-05-29 | 1987-12-03 | Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny I | Antitumor film of biodestructible polymers |
DE3629304A1 (de) * | 1986-08-28 | 1988-03-24 | Lohmann Gmbh & Co Kg | Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung |
AU607172B2 (en) * | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US4855142A (en) * | 1987-02-27 | 1989-08-08 | Ciba-Geigy Corporation | Pharmaceutical plaster |
DE3714140A1 (de) * | 1987-04-28 | 1988-11-10 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut |
HU197519B (en) * | 1987-06-22 | 1989-04-28 | Biogal Gyogyszergyar | Process for producing medicine form capable for penetrating through epidermis and suitable for intaking the agent through epidermis by kinetics of zero-grade |
IE65163B1 (en) * | 1987-06-29 | 1995-10-04 | Squibb & Sons Inc | Process for preparing a wound dressing comprising a hydrophilic acrylic adhesive layer |
-
1989
- 1989-01-20 DE DE3901551A patent/DE3901551A1/de active Granted
- 1989-12-29 IL IL9292489A patent/IL92924A/en not_active IP Right Cessation
- 1989-12-29 AU AU47390/89A patent/AU631167B2/en not_active Ceased
-
1990
- 1990-01-09 YU YU3390A patent/YU47339B/sh unknown
- 1990-01-09 JP JP2001123A patent/JPH0784378B2/ja not_active Expired - Fee Related
- 1990-01-09 CA CA002007353A patent/CA2007353C/en not_active Expired - Fee Related
- 1990-01-10 CZ CS90132A patent/CZ278718B6/cs not_active IP Right Cessation
- 1990-01-10 SK SK132-90A patent/SK13290A3/sk unknown
- 1990-01-16 DK DK90100806.0T patent/DK0379933T3/da active
- 1990-01-16 ES ES90100806T patent/ES2063172T3/es not_active Expired - Lifetime
- 1990-01-16 DE DE59007292T patent/DE59007292D1/de not_active Expired - Fee Related
- 1990-01-16 AT AT90100806T patent/ATE112174T1/de not_active IP Right Cessation
- 1990-01-16 EP EP90100806A patent/EP0379933B1/de not_active Expired - Lifetime
- 1990-01-18 NZ NZ232158A patent/NZ232158A/xx unknown
- 1990-01-18 DD DD90337184A patent/DD291478A5/de not_active IP Right Cessation
- 1990-01-19 HU HU90199A patent/HU205013B/hu not_active IP Right Cessation
- 1990-01-19 FI FI900315A patent/FI104150B/sv not_active IP Right Cessation
- 1990-01-19 PL PL90283353A patent/PL163294B1/pl unknown
- 1990-01-19 IE IE21290A patent/IE66737B1/en not_active IP Right Cessation
- 1990-01-19 KR KR1019900000613A patent/KR960008226B1/ko not_active IP Right Cessation
- 1990-01-19 US US07/467,693 patent/US5077055A/en not_active Expired - Lifetime
- 1990-01-19 PT PT92903A patent/PT92903B/pt not_active IP Right Cessation
- 1990-01-19 NO NO900270A patent/NO300617B1/no not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2223588C (en) | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures | |
US6316022B1 (en) | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures | |
NO180072B (no) | Fremgangsmåte for fremstilling av et transdermalt terapeutisk system med physostigmin som virkestoff | |
NO333297B1 (no) | Forbedret transdermalt leveringssystem for administrering av rotigotin | |
NO300617B1 (no) | Fremgangsmåte for fremstilling av et overflateterapeutisk system | |
NO334187B1 (no) | Forbedret transdermalt leveringssystem | |
US8852628B1 (en) | Transdermal drug delivery system for diclofenac | |
NO177663B (no) | Fremgangsmåte til fremstilling av farmasöytisk preparat med nitroglyserin til perkutan administrering | |
CN115054590B (zh) | 一种稳定的妥洛特罗经皮吸收制剂 | |
JPH07106978B2 (ja) | 複合貼付製剤 | |
JP2007520480A (ja) | 少なくとも一つの脂肪酸を含むジヒドロピリジンタイプのカルシウムアンタゴニスト用の経皮的デリバリー器具 | |
EP0708643A1 (en) | Transdermal melatonin delivery system | |
NO178784B (no) | Fremgangsmåte for fremstilling av et transdermalt terapeutisk system med norpseudoefedrin som virkestoff | |
WO2012072014A1 (zh) | 一种防止雷沙吉兰挥发的透皮贴片 | |
JPH09509154A (ja) | 活性物質モルフィン−6−グルクロニドを含む全身的経皮投与用医薬組成物 | |
CN110869009B (zh) | 氨吡啶tts | |
JPH04244019A (ja) | 医療用貼付剤 | |
HRP930667A2 (en) | Process for the production of top therapeutic system containing antineoplastic active substance, particularly 5-fluorouracil | |
JPH06279288A (ja) | パップ剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN JULY 2002 |